Midatech said it expects that the acquisition of Zuplenz
will leverage its commercial infrastructure in the United States, following the acquisition of DARA BioSciences, and is complementary to Midatech's three existing marketed oncology products.
Strativa Pharmaceuticals launched Oravig[R] and Zuplenz
(ondansetron) in the second half of 2010 and records revenues on an as-prescribed basis.
Biopharmaceutical company Galena Biopharma (NasdaqCM:GALE) reported on Friday the launch of an agreement to divest its Zuplenz
(ondansetron) Oral Soluble Film product to Midatech Pharma valued at up to USD29.75m.
Pharmaceutical company Midatech Pharma (LSE:MTPH.L) revealed on Thursday that it has entered into an agreement to acquire Zuplenz
(ondansetron) for emetogenic chemotherapy-induced nausea and vomiting from Galena Biopharma (NasdaqCM:GALE) for a total up front consideration of USD3.75m in cash.
M2 EQUITYBITES-December 18, 2015-Midatech Pharma to buy Zuplenz
from Galena Biopharma for USD3.75m in cash
It was reported yesterday that the contract has been signed to license the US rights for Zuplenz
(ondansetron) oral soluble film.
This is the second US marketing authorisation for a prescription product based on MonoSol Rx's PharmFilm technology, closely following the July 2010 FDA approval of the anti-emetic Zuplenz
(ondansetron) oral soluble film, MonoSol Rx said.
11 February 2010 - Strativa Pharmaceuticals, the proprietary products division of a wholly-owned subsidiary of Par Pharmaceutical Companies Inc (NYSE: PRX), said last Friday that the US Food and Drug Administration (FDA) has issued a Complete Response letter regarding the New Drug Application (NDA) for Zuplenz
(ondansetron) oral soluble film for the prevention of nausea and vomiting associated with highly- and moderately-emetogenic chemotherapy, radiotherapy and surgery.
M2 EQUITYBITES-July 12, 2011-MonoSol Rx unveils anti-emetic Zuplenz
oral soluble film for licensing to new commercial partners(C)2011 M2 COMMUNICATIONS http://www.m2.com
M2 EQUITYBITES-5 July 2010-Strativa Pharmaceuticals reports FDA approval for Zuplenz
oral soluble film for prevention of chemotherapy-induced, radiotherapy-induced and postoperative nausea and vomiting(C)2010 M2 COMMUNICATIONS http://www.m2.com
Some of the popular brands of hyperemesis gravidarum treatment include Diclectin (Duchesnay Inc.), Pregvit (Duchesnay Inc.), Zofran (Novartis AG), Zuplenz
(Midatech Pharma US Inc.), Kytril (Genentech, Inc.), etc.